Back
Akero Therapeutics Vs. Bowman Consulting Group Industry Stock Comparison
Sell
38
AKRO
Akero Therapeutics
Last Price:
19.72
Seasonality Move:
16.15%
Sell
38
BWMN
Bowman Consulting Group
Last Price:
32.87
Seasonality Move:
-5.05%
Sell
38
Akero Therapeutics (AKRO)
is a Sell
Is Akero Therapeutics a Buy, Sell or Hold?
- The current Akero Therapeutics [AKRO] share price is $19.74. The Score for AKRO is 38, which is 24% below its historic median score of 50, and infers higher risk than normal.
- AKRO is currently trading in the 30-40% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
Sell
38
Bowman Consulting Group (BWMN)
is a Sell
Is Bowman Consulting Group a Buy, Sell or Hold?
- The current Bowman Consulting Group [BWMN] share price is $32.95. The Score for BWMN is 38, which is 24% below its historic median score of 50, and infers higher risk than normal.
- BWMN is currently trading in the 30-40% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
AKRO Stock Price Chart
What is Akero Therapeutics's stock price today?
-
The Akero Therapeutics share price today is $19.74
Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and AKRO is experiencing buying pressure, which is a positive indicator for future bullish movement.
BWMN Stock Price Chart
What is Bowman Consulting Group's stock price today?
-
The Bowman Consulting Group share price today is $32.95
The current trend is relatively stagnant and BWMN is experiencing buying pressure, which is a positive indicator for future bullish movement.
AKRO Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -1.34 | Sell |
| Relative Strength Index (14 RSI): | 33.69 | Sell |
| Chaikin Money Flow: | 413429 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (20.72 - 24.08) | Sell |
| Bollinger Bands (100): | (20.12 - 26.06) | Sell |
BWMN Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -0.97 | Sell |
| Relative Strength Index (14 RSI): | 50.62 | Buy |
| Chaikin Money Flow: | 64449 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (30.15 - 35.93) | Sell |
| Bollinger Bands (100): | (30.95 - 36.57) | Sell |
AKRO Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 20.45 | Sell |
| 20-day SMA: | 21.84 | Sell |
| 50-day SMA: | 24.58 | Sell |
| 200-day SMA: | 28.82 | Sell |
| 8-day EMA: | 20.42 | Sell |
| 20-day EMA: | 21.77 | Sell |
| 50-day EMA: | 23.08 | Sell |
| 200-day EMA: | 27.44 | Sell |
BWMN Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 31.17 | Buy |
| 20-day SMA: | 31.78 | Buy |
| 50-day SMA: | 34.47 | Sell |
| 200-day SMA: | 31.57 | Buy |
| 8-day EMA: | 31.73 | Buy |
| 20-day EMA: | 32.39 | Buy |
| 50-day EMA: | 33.47 | Sell |
| 200-day EMA: | 31.57 | Buy |
Akero Therapeutics Earnings Growth & AKRO Earnings Dates
- Analysts estimate an earnings decrease this quarter of $0.32 per share, a decrease next quarter of $0.19 per share, a decrease this year of $1.01 per share, and a decrease next year of $0.65 per share.
Bowman Consulting Group Earnings Growth & BWMN Earnings Dates
- Analysts estimate an earnings increase this quarter of $0.37 per share, a decrease next quarter of $0.14 per share, an increase this year of $0.61 per share, and an increase next year of $0.38 per share.
Akero Therapeutics Technical Analysis
| Apr 15 | Apr 16 | Apr 17 | Apr 18 | Apr 19 | Apr 22 | Apr 23 | Apr 24 | Apr 25 | Apr 26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr | ||||||||||
| 15 | 16 | 17 | 18 | 19 | 22 | 23 | 24 | 25 | 26 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Bowman Consulting Group Technical Analysis
| Apr 15 | Apr 16 | Apr 17 | Apr 18 | Apr 19 | Apr 22 | Apr 23 | Apr 24 | Apr 25 | Apr 26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr | ||||||||||
| 15 | 16 | 17 | 18 | 19 | 22 | 23 | 24 | 25 | 26 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||